BioMerieux signs agreement with NuGEN Technologies

BioMerieux has signed a new deal with NuGEN Technologies.

The agreement will allow bioMerieux to create and market in vitro diagnostic tests that need amplification for expression analysis.

BioMerieux states that this will allow NuGen access to patented linear amplification technologies using chimeric primers, which will lead to NuGen broadening its intellectual property portfolio.

The agreement also involves a supply agreement for NuGEN’s exclusive WT-Ovation RNA Amplification System.

Elizabeth A Hutt, chief executive officer of NuGEN Technologies, commented: "bioMerieux’s selection is an important validation that WT-Ovation technology will enable a broad range of diagnostic tests for clinical use.

"In this case, it demonstrates that our whole transcriptome strategy can be employed to create IVD assays that will help physicians tailor highly effective therapies for the millions of people stricken each year with cancer."

Biomerieux recently announced increased first-quarter sales in comparison with last year, following strong growth in Europe and North America.